According to Future Market Insights (FMI) analysis in a recent market survey, the global celiac disease diagnostics market was valued at US$ 271.3 Million in 2022 and is expected to reach US$ 647.3 Million by 2033.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 271.3 Million |
| Market Value 2023 | US$ 292.8 Million |
| Market Value 2033 | US$ 647.3 Million |
| CAGR 2023 to 2033 | 8.3% |
| Share of Top 5 Countries | 58.4% |
| Key Players | Thermo Fisher Scientific Inc., PRIMA Lab SA, Glutenostics, Inc., NanoRepro AG., Targeted Genomics, YORKTEST Laboratories, Biohit Oyj, Labsystems Diagnostics Oy, RxHome Test, Biomerica, AESKU.GROUP GmbH, LaCAR MDx Technologies, J. Mitra & Co. Pvt. Ltd., Imaware, Vitrosens Biotechnology, Bio-Rad Laboratories Inc. Eurofins Scientific. |
In Celiac Disease, body's immune system reacts to gluten, a protein found in wheat, rye and barley. This reaction damages the lining of the small intestine and can lead to a range of symptoms, including abdominal pain, bloating, diarrhoea, and weight loss. If left untreated, celiac disease can lead to serious complications, such as malnutrition and an increased risk of certain types of cancer.
Gluten is a protein that is present in wheat, barley, and rye that causes an immunological response in people with celiac disease. In this condition, eating gluten causes the small intestine to launch an immune response, which results in symptoms like diarrhea, bloating, vomiting, or abdominal pain.
Celiac disease is becoming more common across the globe. The increasing cases of celiac disease are linked with decreased microbial diversity compared to our ancestors due to antibiotics, increased C-sections, or low food diversity.
Thus, the increasing cases of celiac disease will lead to increased demand for diagnostics during the forecast period and drive the market growth at a high pace.
Overall, the adoption of celiac diseases diagnostics in healthcare facilities, which will boost the market in the coming years.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales of the celiac disease diagnostics market grew at a CAGR of 5.6% between 2012 to 2022. The Celiac disease diagnostics market contributes 6.4% revenue share to the global autoimmune diseases diagnostics market which is valued at around US$ 4.25 Billion in 2022.
The usage of home-test kits for the diagnosis of celiac disease is leading to a boost for the market. There are several manufacturers that provide kits that help the patients measure their response to gluten and indicate their likelihood of having the disease.
The sample needed for the home test kits generally includes blood or swab. The results during the home test could be mailed to a lab for analysis. The labs generally provide easy-to-understand results within 5 to 7 business days that could be shown to healthcare professionals.
Several manufacturers are involved in increased product launches for at-home test products.
Governments around the world are taking initiatives to increase awareness about celiac disease and improve access to diagnostics and treatment. For example, some countries have introduced screening programs for celiac disease in high-risk populations. Point-of-care testing (POCT) for celiac disease is becoming increasingly popular as it allows for rapid diagnosis and treatment. POCT is especially useful in remote or underserved areas where access to laboratory testing may be limited.
Considering this, FMI expects the global market to grow at a CAGR of 8.3% through the forecasted years.
Technological advances related to sample collection and efforts of manufacturers to create easy-to-use kits are increasing the demand for the market.
Manufacturers are focusing on using non-invasive options such as cheek swabs, which are easier to use and do not cause pain. The result could also be obtained in a few days and thus the adoption is high.
The use of newer diagnostic tools, including deamidated gliadin peptide, serologic tests for antibodies against tissue transglutaminase (tTG), greatly facilitates diagnosis. Tests for DQ8 molecules and celiac-permissive HLA DQ2 are also useful in defined clinical situations. These diagnostic options are widely being adopted to improve the diagnostic approaches for celiac disease.
Thus, with the easy diagnosis of celiac disease, there are increased opportunities for new and emerging manufacturers in the market of celiac disease diagnostics. Further investment by key players could also create opportunities in the market of celiac disease diagnostics.
Principal Consultant
The procedure of testing for celiac disease is quite simple and the at-home celiac disease testing rate is also high. Although the testing kits claim to have high precision, there could be chances of inconsistency in the result as a result of false results.
There are several factors that lead to such instances such as the type of test, type of sample, and other similar factors.
These factors are expected to hamper revenue growth of the celiac disease diagnostics market over the forecast period.
The USA market is expected to register a CAGR of 7.6% during the forecast period.
Celiac disease is a relatively common autoimmune disorder, but its prevalence can vary across different populations and regions. In the United States, celiac disease is considered to be underdiagnosed, with a significant number of cases remaining undiagnosed or misdiagnosed.
Due to the high prevalence, more treatments, products will experience a high adoption rate among patients. The demand for celiac disease diagnostics will increase due to high prevalence, which will drive the expansion of the market.
Germany dominated the European market for celiac disease diagnostics and accounted for around 25.6% of the market share in 2022.
Increasing technological advancements in celiac disease diagnostics in Germany is driving the overall Europe market. These advancements aim to improve the accuracy, efficiency, and convenience of diagnosing and managing the condition. Here are a few notable technological advancements in Germany for celiac disease diagnostics
Additionally, Genetic testing plays a role in identifying certain genetic markers associated with celiac disease. Germany, like other countries, has seen advancements in genetic testing technologies, making it easier and more accessible to analyze an individual's genetic profile to determine the presence of genes like HLA-DQ2 and HLA-DQ8, which are associated with an increased risk of developing celiac disease. Genetic testing can help in cases where there is diagnostic uncertainty or when other diagnostic methods are inconclusive, ultimately expanding the overall market.
China is projected to be the most attractive market in the celiac disease diagnostics, and is expected to grow over a significant CAGR of 9.9%.
The celiac disease diagnostics market in China is expected to grow significantly in the coming years due to several factors.
One of the main factors driving the growth of the celiac disease diagnostics in China is the increasing awareness of the condition among the general public and healthcare professionals. As more people become aware of the condition, they are more likely to seek diagnostics and treatment, which is leading to increased demand for diagnostics for celiac disease.
Another factor contributing to the growth of the China market is the increasing availability of advanced medical technologies and treatments. China has made significant investments in its healthcare infrastructure, and many new hospitals and clinics have been built in recent years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The serology rapid testing kits segment held the major chunk of about 72.4% in global market by the end of 2022.
Serology rapid testing kits provide quick results, often within minutes, allowing for immediate diagnosis or screening. This speed is particularly beneficial in situations where prompt decision-making is necessary, such as in point-of-care settings or during emergency situations.
Serology rapid testing kits enable testing to be conducted at the point of care, eliminating the need for sending samples to a laboratory. This convenience improves accessibility, especially in remote or resource-limited areas, where access to laboratory facilities may be challenging.
The ELISA segment held the major chunk of about 56.7% in global market by the end of 2022.
The enzyme-linked immunosorbent assay (ELISA) technique has been widely used in celiac disease diagnostics for many years and continues to be an essential tool in this field. ELISA is a laboratory-based test that measures the presence and concentration of specific antibodies in a patient's blood sample.
ELISA has demonstrated high sensitivity and specificity in detecting celiac-specific antibodies. Sensitivity refers to the ability of the test to correctly identify individuals with celiac disease, while specificity refers to its ability to correctly identify individuals without the disease. ELISA tests designed for celiac disease diagnostics have been optimized to achieve reliable and accurate results. This is adding value to the market.
The blood serum segment accounted for revenue share of 74.1% in the global market at the end of 2022.
Blood serum plays a crucial role in celiac disease diagnostics. It is used to analyze various biomarkers and antibodies associated with the condition. Serologic tests measure specific antibodies present in the blood serum that indicate an immune response to gluten. These tests are the primary screening method for celiac disease. The most commonly measured antibodies include tissue transglutaminase antibodies (tTG), deamidated gliadin peptide antibodies (DGP), and endomysial antibodies (EMA).
Blood serum provides valuable information in celiac disease diagnostics, allowing healthcare professionals to assess antibody levels, detect IgA deficiency, monitor disease progression, and evaluate treatment response.
The diagnostic laboratories segment accounted for revenue share of 44.0% in the global market at the end of 2022.
Diagnostic laboratories play a crucial role in celiac disease diagnostics. These specialized laboratories perform a range of tests and analyses to aid in the accurate diagnosis and monitoring of the condition. Diagnostic laboratories also contribute to research and development efforts in celiac disease diagnostics. They participate in studies and clinical trials to explore new diagnostic methods, evaluate the performance of novel biomarkers, and enhance the accuracy and efficiency of existing tests.
Key players in the market are focused on increase their product portfolio to strengthen their position in the market, and also to expand their footprint in emerging markets. The key strategy adopted by manufacturers to gain competitive edge in the market are the partnerships and acquisition of other companies to expand their business.
For instance:
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the celiac disease diagnostics market space, which are available in the full report
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2012 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East; and Africa (MEA) |
| Key Countries Covered | US, Canada, Brazil, Mexico, Argentina, Germany, U.K., France, Italy, Spain, Russia, BENELUX, Nordics, India, Thailand, Indonesia, Malaysia, Philippines, Vietnam, China, Japan, South Korea, Australia, New Zealand, Türkiye, Israel, South Africa, North Africa, and GCC Countries |
| Key Segments Covered | Product, Technique, Sample, End User, and Region |
| Key Companies Profiled | Thermo Fisher Scientific Inc.; PRIMA Lab SA; Glutenostics, Inc.; NanoRepro AG.; Targeted Genomics; YORKTEST Laboratories; Biohit Oyj; Labsystems Diagnostics Oy; RxHome Test; Biomerica; AESKU.GROUP GmbH; LaCAR MDx Technologies; J. Mitra & Co. Pvt. Ltd.; Imaware; Vitrosens Biotechnology; Bio-Rad Laboratories Inc.; Eurofins Scientific |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
Chantal Guillon, Dana’s Bakery, and Dollayau are the top manufacturers in the United States and Europe.
The net worth of the market is almost US$ 292.8 million in 2023.
The net revenue is likely to surpass US$ 647.3 million by 2033.
The demand in China is expected to surge at 9.9% CAGR through 2033.
Serology rapid testing kit segment share was nearly 72.4% in 2022.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value-Added Insights
4.1. Disease Epidemiology
4.2. Pipeline Assessment
4.3. Product Adoption/Usage Analysis
4.4. Regulatory Scenario
4.5. Reimbursement Guidelines
4.6. PESTLE Analysis
4.7. Porter’s Analysis
4.8. Value Chain Analysis
4.9. Industry Leaders | Key Promotional Strategies
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global Autoimmune Diseases Diagnostics Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Growth in Healthcare Spending
5.2.2. Increase in Diagnosis of Celiac Disease
5.2.3. Growth in Geriatric Population
5.2.4. Product Launches
5.2.5. Increasing Research and Development
5.2.6. Collaborations With e-Commerce Partners
5.2.7. Regulatory Impositions
5.2.8. Strategic Mergers and Acquisitions Among Local Manufacturers
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Product
6.1.2. By Technique
6.1.3. By Sample
6.1.4. By Distribution Channel
6.1.5. By Region
6.2. 2022 Market Scenario
7. Global Market Demand (in Volume (Units) Analysis 2012 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Volume (Units) Analysis, 2012 to 2022
7.2. Current and Future Market Volume (Units) (Units) Projections, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
8. Global Market - Pricing Analysis
8.1. Regional Pricing Analysis By Product
8.2. Pricing Break-up
8.2.1. Manufacturer-Level Pricing
8.2.2. Distributor Level Pricing
8.3. Global Average Pricing Analysis Benchmark
8.4. Pricing Assumptions
9. Global Market Demand (in Value US$ Million) Analysis 2012 to 2022 and Forecast, 2023 to 2033
9.1. Historical Market Value (US$ Million) Analysis, 2012 to 2022
9.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
9.2.1. Y-o-Y Growth Trend Analysis
9.2.2. Absolute $ Opportunity Analysis
9.3. Revenue Opportunity Scenario
10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Product
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, by Product, 2012 to 2022
10.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast, by Product, 2023 to 2033
10.3.1. Serology Rapid Testing Kits
10.3.1.1. Transglutaminase Antibody Test Kits
10.3.1.2. Endomysial Antibody Test Kits
10.3.1.3. Anti-Giladin Antibody Test Kits
10.3.2. Genetic Rapid Testing Kits
10.4. Market Attractiveness Analysis, by Product
11. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Technique
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis, By Technique, 2012 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast, by Technique, 2023 to 2033
11.3.1. Immunochromatography (Lateral Flow)
11.3.2. ELISA (enzyme-linked immunosorbent assay)
11.4. Market Attractiveness Analysis, by Technique
12. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Sample
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis, By Sample, 2012 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast, by Sample, 2023 to 2033
12.3.1. Blood Serum
12.3.2. Body Fluids
12.4. Market Attractiveness Analysis, by Sample
13. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By End User
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Million) Analysis, By End User, 2012 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast, by End User, 2023 to 2033
13.3.1. Hospitals
13.3.2. Diagnostic Laboratories
13.3.3. Specialty Clinics
13.3.4. Home Care Setting
13.4. Market Attractiveness Analysis, by End User
14. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Region
14.1. Introduction
14.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, by Region, 2012 to 2022
14.3. Current and Future Market Value (US$ Million) Volume (Units) Analysis and Forecast, By Region, 2023 to 2033
14.3.1. North America
14.3.2. Latin America
14.3.3. Europe
14.3.4. South Asia
14.3.5. East Asia
14.3.6. Oceania
14.3.7. Middle East and Africa (MEA)
14.4. Market Attractiveness Analysis, by Region
15. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, by Market Taxonomy, 2012 to 2022
15.3. Current and Future Market Value (US$ Million) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. USA
15.3.1.2. Canada
15.3.2. By Product
15.3.3. By Technique
15.3.4. By Sample
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product
15.4.3. By Technique
15.4.4. By Sample
15.4.5. By End User
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country-Level Analysis & Forecast
15.8.1. USA Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast, by Market Taxonomy
15.8.1.2.1. By Product
15.8.1.2.2. By Technique
15.8.1.2.3. By Sample
15.8.1.2.4. By End User
15.8.2. Canada Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast, by Market Taxonomy
15.8.2.2.1. By Product
15.8.2.2.2. By Technique
15.8.2.2.3. By Sample
15.8.2.2.4. By End User
16. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, by Market Taxonomy, 2012 to 2022
16.3. Current and Future Market Value (US$ Million) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. Mexico
16.3.1.2. Brazil
16.3.1.3. Argentina
16.3.1.4. Rest of Latin America
16.3.2. By Product
16.3.3. By Technique
16.3.4. By Sample
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product
16.4.3. By Technique
16.4.4. By Sample
16.4.5. By End User
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country-Level Analysis & Forecast
16.8.1. Mexico Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast, by Market Taxonomy
16.8.1.2.1. By Product
16.8.1.2.2. By Technique
16.8.1.2.3. By Sample
16.8.1.2.4. By End User
16.8.2. Brazil Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast, by Market Taxonomy
16.8.2.2.1. By Product
16.8.2.2.2. By Technique
16.8.2.2.3. By Sample
16.8.2.2.4. By End User
16.8.3. Argentina Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast, by Market Taxonomy
16.8.3.2.1. By Product
16.8.3.2.2. By Technique
16.8.3.2.3. By Sample
16.8.3.2.4. By End User
17. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, by Market Taxonomy, 2012 to 2022
17.3. Current and Future Market Value (US$ Million) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. Germany
17.3.1.2. Italy
17.3.1.3. France
17.3.1.4. United Kingdom
17.3.1.5. Spain
17.3.1.6. BENELUX
17.3.1.7. Russia
17.3.1.8. Nordic Countries
17.3.1.9. Rest of Europe
17.3.2. By Product
17.3.3. By Technique
17.3.4. By Sample
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product
17.4.3. By Technique
17.4.4. By Sample
17.4.5. By End User
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country-Level Analysis & Forecast
17.8.1. Germany Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast, by Market Taxonomy
17.8.1.2.1. By Product
17.8.1.2.2. By Technique
17.8.1.2.3. By Sample
17.8.1.2.4. By End User
17.8.2. Italy Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast, by Market Taxonomy
17.8.2.2.1. By Product
17.8.2.2.2. By Technique
17.8.2.2.3. By Sample
17.8.2.2.4. By End User
17.8.3. France Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast, by Market Taxonomy
17.8.3.2.1. By Product
17.8.3.2.2. By Technique
17.8.3.2.3. By Sample
17.8.3.2.4. By End User
17.8.4. United Kingdom Market Analysis
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast, by Market Taxonomy
17.8.4.2.1. By Product
17.8.4.2.2. By Technique
17.8.4.2.3. By Sample
17.8.4.2.4. By End User
17.8.5. Spain Market Analysis
17.8.5.1. Introduction
17.8.5.2. Market Analysis and Forecast, by Market Taxonomy
17.8.5.2.1. By Product
17.8.5.2.2. By Technique
17.8.5.2.3. By Sample
17.8.5.2.4. By End User
17.8.6. BENELUX Market Analysis
17.8.6.1. Introduction
17.8.6.2. Market Analysis and Forecast, by Market Taxonomy
17.8.6.2.1. By Product
17.8.6.2.2. By Technique
17.8.6.2.3. By Sample
17.8.6.2.4. By End User
17.8.7. Russia Market Analysis
17.8.7.1. Introduction
17.8.7.2. Market Analysis and Forecast, by Market Taxonomy
17.8.7.2.1. By Product
17.8.7.2.2. By Technique
17.8.7.2.3. By Sample
17.8.7.2.4. By End User
17.8.8. Nordic Countries Market Analysis
17.8.8.1. Introduction
17.8.8.2. Market Analysis and Forecast, by Market Taxonomy
17.8.8.2.1. By Product
17.8.8.2.2. By Technique
17.8.8.2.3. By Sample
17.8.8.2.4. By End User
18. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market End User (US$ Million) Analysis, by Market Taxonomy, 2012 to 2022
18.3. Current and Future Market Value (US$ Million) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. China
18.3.1.2. Japan
18.3.1.3. South Korea
18.3.2. By Product
18.3.3. By Technique
18.3.4. By Sample
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Product
18.4.3. By Technique
18.4.4. By Sample
18.4.5. By End User
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country-Level Analysis & Forecast
18.8.1. China Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast, by Market Taxonomy
18.8.1.2.1. By Product
18.8.1.2.2. By Technique
18.8.1.2.3. By Sample
18.8.1.2.4. By End User
18.8.2. Japan Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast, by Market Taxonomy
18.8.2.2.1. By Product
18.8.2.2.2. By Technique
18.8.2.2.3. By Sample
18.8.2.2.4. By End User
18.8.3. South Korea Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast, by Market Taxonomy
18.8.3.2.1. By Product
18.8.3.2.2. By Technique
18.8.3.2.3. By Sample
18.8.3.2.4. By End User
19. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, by Market Taxonomy, 2012 to 2022
19.3. Current and Future Market Value (US$ Million) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. India
19.3.1.2. Indonesia
19.3.1.3. Malaysia
19.3.1.4. Thailand
19.3.1.5. Philippines
19.3.1.6. Vietnam
19.3.1.7. Rest of South Asia
19.3.2. By Product
19.3.3. By Technique
19.3.4. By Sample
19.3.5. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Product
19.4.3. By Technique
19.4.4. By Sample
19.4.5. By End User
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country-Level Analysis & Forecast
19.8.1. India Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast, by Market Taxonomy
19.8.1.2.1. By Product
19.8.1.2.2. By Technique
19.8.1.2.3. By Sample
19.8.1.2.4. By End User
19.8.2. Indonesia Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast, by Market Taxonomy
19.8.2.2.1. By Product
19.8.2.2.2. By Technique
19.8.2.2.3. By Sample
19.8.2.2.4. By End User
19.8.3. Malaysia Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast, by Market Taxonomy
19.8.3.2.1. By Product
19.8.3.2.2. By Technique
19.8.3.2.3. By Sample
19.8.3.2.4. By End User
19.8.4. Thailand Market Analysis
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast, by Market Taxonomy
19.8.4.2.1. By Product
19.8.4.2.2. By Technique
19.8.4.2.3. By Sample
19.8.4.2.4. By End User
19.8.5. Philippines Market Analysis
19.8.5.1. Introduction
19.8.5.2. Market Analysis and Forecast, by Market Taxonomy
19.8.5.2.1. By Product
19.8.5.2.2. By Technique
19.8.5.2.3. By Sample
19.8.5.2.4. By End User
19.8.6. Vietnam Market Analysis
19.8.6.1. Introduction
19.8.6.2. Market Analysis and Forecast, by Market Taxonomy
19.8.6.2.1. By Product
19.8.6.2.2. By Technique
19.8.6.2.3. By Sample
19.8.6.2.4. By End User
20. Oceania Market 2012 to 2022 and Forecast 2022 to 2033
20.1. Introduction
20.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, by Market Taxonomy, 2012 to 2022
20.3. Current and Future Market Value (US$ Million) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2023 to 2033
20.3.1. By Country
20.3.1.1. Australia
20.3.1.2. New Zealand
20.3.2. By Product
20.3.3. By Technique
20.3.4. By Sample
20.3.5. By End User
20.4. Market Attractiveness Analysis
20.4.1. By Country
20.4.2. By Product
20.4.3. By Technique
20.4.4. By Sample
20.4.5. By End User
20.5. Market Trends
20.6. Key Market Participants – Intensity Mapping
20.7. Drivers and Restraints - Impact Analysis
20.8. Country-Level Analysis & Forecast
20.8.1. Australia Market Analysis
20.8.1.1. Introduction
20.8.1.2. Market Analysis and Forecast, by Market Taxonomy
20.8.1.2.1. By Product
20.8.1.2.2. By Technique
20.8.1.2.3. By Sample
20.8.1.2.4. By End User
20.8.2. New Zealand Market Analysis
20.8.2.1. Introduction
20.8.2.2. Market Analysis and Forecast, by Market Taxonomy
20.8.2.2.1. By Product
20.8.2.2.2. By Technique
20.8.2.2.3. By Sample
20.8.2.2.4. By End User
21. Middle East and Africa (MEA) Market Analysis 2012 to 2022 and Forecast 2023 to 2033
21.1. Introduction
21.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, by Market Taxonomy, 2012 to 2022
21.3. Current and Future Market Value (US$ Million) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2023 to 2033
21.3.1. By Country
21.3.1.1. GCC Countries
21.3.1.2. Türkiye
21.3.1.3. Israel
21.3.1.4. South Africa
21.3.1.5. North Africa
21.3.1.6. Rest of Middle East and Africa
21.3.2. By Product
21.3.3. By Technique
21.3.4. By Sample
21.3.5. By End User
21.4. Market Attractiveness Analysis
21.4.1. By Country
21.4.2. By Product
21.4.3. By Technique
21.4.4. By Sample
21.4.5. By End User
21.5. Market Trends
21.6. Key Market Participants - Intensity Mapping
21.7. Drivers and Restraints - Impact Analysis
21.8. Country-Level Analysis & Forecast
21.8.1. GCC Countries Market Analysis
21.8.1.1. Introduction
21.8.1.2. Market Analysis and Forecast, by Market Taxonomy
21.8.1.2.1. By Product
21.8.1.2.2. By Technique
21.8.1.2.3. By Sample
21.8.1.2.4. By End User
21.8.2. Türkiye Market Analysis
21.8.2.1. Introduction
21.8.2.2. Market Analysis and Forecast, by Market Taxonomy
21.8.2.2.1. By Product
21.8.2.2.2. By Technique
21.8.2.2.3. By Sample
21.8.2.2.4. By End User
21.8.3. Israel Africa Market Analysis
21.8.3.1. Introduction
21.8.3.2. Market Analysis and Forecast, by Market Taxonomy
21.8.3.2.1. By Product
21.8.3.2.2. By Technique
21.8.3.2.3. By Sample
21.8.3.2.4. By End User
21.8.4. South Africa Market Analysis
21.8.4.1. Introduction
21.8.4.2. Market Analysis and Forecast, by Market Taxonomy
21.8.4.2.1. By Product
21.8.4.2.2. By Technique
21.8.4.2.3. By Sample
21.8.4.2.4. By End User
21.8.5. North Africa Market Analysis
21.8.5.1. Introduction
21.8.5.2. Market Analysis and Forecast, by Market Taxonomy
21.8.5.2.1. By Product
21.8.5.2.2. By Technique
21.8.5.2.3. By Sample
21.8.5.2.4. By End User
22. Market Structure Analysis
22.1. Market Analysis, by Tier of Companies
22.2. Market Share Analysis of Top Players
22.3. Market Presence Analysis
23. Competition Analysis
23.1. Competition Dashboard
23.2. Competition Benchmarking
23.3. Key Development Analysis
23.4. Competition Deep Dive
23.4.1. Thermo Fisher Scientific Inc.
23.4.1.1. Overview
23.4.1.2. Product Portfolio
23.4.1.3. Sales Footprint
23.4.1.4. Key Financials
23.4.1.5. SWOT Analysis
23.4.1.6. Key Developments
23.4.1.7. Strategy Overview
23.4.1.7.1. Marketing Strategy
23.4.1.7.2. Product Strategy
23.4.1.7.3. Channel Strategy
23.4.2. PRIMA Lab SA
23.4.2.1. Overview
23.4.2.2. Product Portfolio
23.4.2.3. Sales Footprint
23.4.2.4. Key Financials
23.4.2.5. SWOT Analysis
23.4.2.6. Key Developments
23.4.2.7. Strategy Overview
23.4.2.7.1. Marketing Strategy
23.4.2.7.2. Product Strategy
23.4.2.7.3. Channel Strategy
23.4.3. Glutenostics, Inc.
23.4.3.1. Overview
23.4.3.2. Product Portfolio
23.4.3.3. Sales Footprint
23.4.3.4. Key Financials
23.4.3.5. SWOT Analysis
23.4.3.6. Key Developments
23.4.3.7. Strategy Overview
23.4.3.7.1. Marketing Strategy
23.4.3.7.2. Product Strategy
23.4.3.7.3. Channel Strategy
23.4.4. NanoRepro AG.
23.4.4.1. Overview
23.4.4.2. Product Portfolio
23.4.4.3. Sales Footprint
23.4.4.4. Key Financials
23.4.4.5. SWOT Analysis
23.4.4.6. Key Developments
23.4.4.7. Strategy Overview
23.4.4.7.1. Marketing Strategy
23.4.4.7.2. Product Strategy
23.4.4.7.3. Channel Strategy
23.4.5. Targeted Genomics
23.4.5.1. Overview
23.4.5.2. Product Portfolio
23.4.5.3. Sales Footprint
23.4.5.4. Key Financials
23.4.5.5. SWOT Analysis
23.4.5.6. Key Developments
23.4.5.7. Strategy Overview
23.4.5.7.1. Marketing Strategy
23.4.5.7.2. Product Strategy
23.4.5.7.3. Channel Strategy
23.4.6. YORKTEST Laboratories
23.4.6.1. Overview
23.4.6.2. Product Portfolio
23.4.6.3. Sales Footprint
23.4.6.4. Key Financials
23.4.6.5. SWOT Analysis
23.4.6.6. Key Developments
23.4.6.7. Strategy Overview
23.4.6.7.1. Marketing Strategy
23.4.6.7.2. Product Strategy
23.4.6.7.3. Channel Strategy
23.4.7. Biohit Oyj
23.4.7.1. Overview
23.4.7.2. Product Portfolio
23.4.7.3. Sales Footprint
23.4.7.4. Key Financials
23.4.7.5. SWOT Analysis
23.4.7.6. Key Developments
23.4.7.7. Strategy Overview
23.4.7.7.1. Marketing Strategy
23.4.7.7.2. Product Strategy
23.4.7.7.3. Channel Strategy
23.4.8. Labsystems Diagnostics Oy
23.4.8.1. Overview
23.4.8.2. Product Portfolio
23.4.8.3. Sales Footprint
23.4.8.4. Key Financials
23.4.8.5. SWOT Analysis
23.4.8.6. Key Developments
23.4.8.7. Strategy Overview
23.4.8.7.1. Marketing Strategy
23.4.8.7.2. Product Strategy
23.4.8.7.3. Channel Strategy
23.4.9. RxHome Test
23.4.9.1. Overview
23.4.9.2. Product Portfolio
23.4.9.3. Sales Footprint
23.4.9.4. Key Financials
23.4.9.5. SWOT Analysis
23.4.9.6. Key Developments
23.4.9.7. Strategy Overview
23.4.9.7.1. Marketing Strategy
23.4.9.7.2. Product Strategy
23.4.9.7.3. Channel Strategy
23.4.10. Biomerica
23.4.10.1. Overview
23.4.10.2. Product Portfolio
23.4.10.3. Sales Footprint
23.4.10.4. Key Financials
23.4.10.5. SWOT Analysis
23.4.10.6. Key Developments
23.4.10.7. Strategy Overview
23.4.10.7.1. Marketing Strategy
23.4.10.7.2. Product Strategy
23.4.10.7.3. Channel Strategy
23.4.11. AESKU.GROUP GmbH
23.4.11.1. Overview
23.4.11.2. Product Portfolio
23.4.11.3. Sales Footprint
23.4.11.4. Key Financials
23.4.11.5. SWOT Analysis
23.4.11.6. Key Developments
23.4.11.7. Strategy Overview
23.4.11.7.1. Marketing Strategy
23.4.11.7.2. Product Strategy
23.4.11.7.3. Channel Strategy
23.4.12. LaCAR MDx Technologies
23.4.12.1. Overview
23.4.12.2. Product Portfolio
23.4.12.3. Sales Footprint
23.4.12.4. Key Financials
23.4.12.5. SWOT Analysis
23.4.12.6. Key Developments
23.4.12.7. Strategy Overview
23.4.12.7.1. Marketing Strategy
23.4.12.7.2. Product Strategy
23.4.12.7.3. Channel Strategy
23.4.13. J. Mitra & Co. Pvt. Ltd.
23.4.13.1. Overview
23.4.13.2. Product Portfolio
23.4.13.3. Sales Footprint
23.4.13.4. Key Financials
23.4.13.5. SWOT Analysis
23.4.13.6. Key Developments
23.4.13.7. Strategy Overview
23.4.13.7.1. Marketing Strategy
23.4.13.7.2. Product Strategy
23.4.13.7.3. Channel Strategy
23.4.14. Imaware
23.4.14.1. Overview
23.4.14.2. Product Portfolio
23.4.14.3. Sales Footprint
23.4.14.4. Key Financials
23.4.14.5. SWOT Analysis
23.4.14.6. Key Developments
23.4.14.7. Strategy Overview
23.4.14.7.1. Marketing Strategy
23.4.14.7.2. Product Strategy
23.4.14.7.3. Channel Strategy
23.4.15. Vitrosens Biotechnology
23.4.15.1. Overview
23.4.15.2. Product Portfolio
23.4.15.3. Sales Footprint
23.4.15.4. Key Financials
23.4.15.5. SWOT Analysis
23.4.15.6. Key Developments
23.4.15.7. Strategy Overview
23.4.15.7.1. Marketing Strategy
23.4.15.7.2. Product Strategy
23.4.15.7.3. Channel Strategy
23.4.16. Bio-Rad Laboratories Inc.
23.4.16.1. Overview
23.4.16.2. Product Portfolio
23.4.16.3. Sales Footprint
23.4.16.4. Key Financials
23.4.16.5. SWOT Analysis
23.4.16.6. Key Developments
23.4.16.7. Strategy Overview
23.4.16.7.1. Marketing Strategy
23.4.16.7.2. Product Strategy
23.4.16.7.3. Channel Strategy
23.4.17. Eurofins Scientific
23.4.17.1. Overview
23.4.17.2. Product Portfolio
23.4.17.3. Sales Footprint
23.4.17.4. Key Financials
23.4.17.5. SWOT Analysis
23.4.17.6. Key Developments
23.4.17.7. Strategy Overview
23.4.17.7.1. Marketing Strategy
23.4.17.7.2. Product Strategy
23.4.17.7.3. Channel Strategy
24. Assumptions and Acronyms Used
25. Research Methodology
Explore Healthcare Insights
View Reports
Celiac Disease Diagnostics Market
